Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2025-12-25 @ 1:33 AM
NCT ID:
NCT04412694
Eligibility Criteria:
Inclusion Criteria:
* patient's consent
* adult patients
* preoperative diagnosis of nontoxic multinodular goiter
* total thyroidectomy
Exclusion Criteria:
* lack of patient's consent
* hyperthyroidism currently or in the past
* retrosternal goiter
* thyroid malignanacy or suspected malignant thyroid tumor
* parathyroids disease
* malingant tumor in any location currently or in the past
* state after neck surgery
* state after radiotherapy
* bone diseases, osteoporosis
* sarcoidosis
* liver failure, hepatitis
* kidney stones, kidney failure (eGFR\<60ml/min/1.73m2)
* taking nonsteroidal anti-inflammatory drugs
* steroid treatment
* stomach and duodenal ulcer disease currently or in the past
* active infection at the time of the study
* history of tuberculosis
* a period of 8 weeks before and 2 weeks after administration of the live vaccine
* unregulated hypertension
* diabetes
* psychiatric disorders
* glaucoma
* corneal ulcers or corneal injuries
* severe heart failure
* pheochromocytoma
* myasthenia gravis
* epilepsy
* head injury
* ulcerative colitis
* diverticulitis
* pregnancy
* breast-feeding
* hypokalaemia
* galactose intolerance
* lactase deficiency
* dexamethasone allergy, allergic to lactose, allergic to gelatinized starch, allergic to corn starch, allergic to colloidal anhydrous silica, allergic to magnesium stearate
* allergic reaction to substances contained in the sweetener: sodium cyclamate, sodium saccharin, sodium bicarbonate, sodium citrate.
* taking medications that affect calcium metabolism: anti-resorptive drugs, anabolic drugs, bisphosphonates, systemic glucocorticosteroids, thiazide diuretics, furosemide, proton pump inhibitors, antacids containing magnesium or aluminum salts, cholestyramine, colestipol, paraffin oil, salicylates, estrogen-containing oral contraceptives (hormonal contraceptives) , preparations containing calcium salts (regular intake), preparations of vitamin D or its analogues (regular intake)
* taking medications that increase the side effect of dexamethasone or enter into drug interactions with dexamethasone: acetazolamide, loop diuretics, thiazide diuretics, diuretics, amphotericin B, glucocorticosteroids, mineralocorticosteroids, tetracosactide and laxatives, carbenoxolone, chlorokine, hydroxychlorokine and meflocin, angiotensin converting enzyme inhibitors, thalidomide, cholinesterase inhibitors in patients with myasthenia gravis, fluorochonolones, ephedrine, barbiturates, rifabutin, rifampicin, phenytoin and carbamazepine, aminoglutethimide, bile acid binding resins, such as cholestyramine, antacids,activated carbon, antifungal azoles, ketoconazole, HIV protease inhibitors, macrolide antibiotics, estrogens, anti-tuberculosis drugs (isoniazid), cyclosporin, praziquantel, oral anticoagulants (coumarin), atropine and other anticholinergic drugs, somatotropin, protirel.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
100 Years
Study:
NCT04412694
Study Brief:
Protocol Section:
NCT04412694